Zai Lab Limited American Depositary Shares (ZLAB) Stock Price

ZLABStock

$23.19−17.46%52W

Market Cap$2.60B

P/E—

PEG Ratio—

Div yield—

Beta0.27

ZLAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.86%

Price vs S&P 500 (4W)-8.30%

VGM Score58.24

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)3.09x

Revenue Growth (3Y)28.86%

Cash Flow / Share (Quarterly)$-0.14

Price vs S&P 500 (YTD)25.58%

Gross Margin (TTM)60.50%

Net Profit Margin (TTM)-41.86%

EPS (TTM)$-0.17

10-Day Avg Trading Volume3.77M

EPS Excl Extra (TTM)$-0.17

Revenue Growth (5Y)56.51%

EPS (Annual)$-0.16

ROI (Annual)-19.08%

Gross Margin (Annual)61.15%

Net Profit Margin (5Y Avg)-184.48%

Cash / Share (Quarterly)$0.55

Revenue Growth QoQ (YoY)-3.33%

ROA (Last FY)-14.97%

Revenue Growth TTM (YoY)5.10%

EBITD / Share (TTM)$-0.22

ROE (5Y Avg)-38.12%

Operating Margin (TTM)-58.74%

Cash Flow / Share (Annual)$-0.15

P/B Ratio4.28x

P/B Ratio (Quarterly)3.45x

Net Income / Employee (Annual)$-147,000

EV / Revenue (TTM)4.96x

Net Interest Coverage (TTM)-9.59x

ROA (TTM)-16.72%

EPS Incl Extra (Annual)$-0.16

Current Ratio (Annual)2.45x

Quick Ratio (Quarterly)1.84x

3-Month Avg Trading Volume8.62M

52-Week Price Return-17.46%

Revenue / Employee (TTM)$376,600

Tangible BV / Share (Quarterly)$0.46

P/S Ratio (Annual)5.64x

Asset Turnover (Annual)0.39x

52-Week High$24.76

Operating Margin (5Y Avg)-186.24%

EPS Excl Extra (Annual)$-0.16

CapEx CAGR (5Y)4.70%

Tangible BV CAGR (5Y)-11.31%

26-Week Price Return13.76%

Quick Ratio (Annual)2.18x

13-Week Price Return20.00%

Total Debt / Equity (Annual)0.29x

Current Ratio (Quarterly)2.13x

Enterprise Value$2.23B

Revenue / Share Growth (5Y)46.10%

Asset Turnover (TTM)0.40x

Book Value / Share Growth (5Y)-13.45%

Revenue / Employee (Annual)$385,400

Inventory Turnover (Annual)3.12x

Pretax Margin (Annual)-38.78%

Cash / Share (Annual)$0.62

3-Month Return Std Dev63.17%

Gross Margin (5Y Avg)63.56%

Net Income / Employee (TTM)$-157,600

ROE (Last FY)-24.53%

Net Interest Coverage (Annual)-9.67x

EPS Basic Excl Extra (Annual)$-0.16

Receivables Turnover (TTM)5.69x

Total Debt / Equity (Quarterly)0.39x

EPS Incl Extra (TTM)$-0.17

Receivables Turnover (Annual)4.81x

ROI (TTM)-20.89%

P/S Ratio (TTM)5.78x

Pretax Margin (5Y Avg)-184.44%

Revenue / Share (Annual)$0.42

Tangible BV / Share (Annual)$0.58

Price vs S&P 500 (52W)-17.82%

Year-to-Date Return36.26%

5-Day Price Return-3.68%

EPS Normalized (Annual)$-0.16

ROA (5Y Avg)-29.81%

Net Profit Margin (Annual)-38.15%

Month-to-Date Return-9.88%

Cash Flow / Share (TTM)$-2.36

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-49.86%

ROI (5Y Avg)-36.20%

EPS Basic Excl Extra (TTM)$-0.17

P/TBV (Quarterly)4.04x

P/B Ratio (Annual)2.75x

Inventory Turnover (TTM)2.33x

Pretax Margin (TTM)-42.42%

Book Value / Share (Annual)$0.65

Price vs S&P 500 (13W)17.31%

Beta0.27x

Revenue / Share (TTM)$0.40

ROE (TTM)-27.43%

52-Week Low$12.31

vGradeC

gGradeC

mGradeB

vgmGradeC

ZLAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.68	-$0.46	+32.29%(+$0.22)
Q1 2026	May 7, 2026	-$0.53	-$0.46	+12.57%(+$0.07)
Q4 2025	Feb 26, 2026	-$0.42	-$0.46	-8.45%(-$0.04)
Q3 2025	Nov 6, 2025	-$0.29	-$0.33	-12.87%(-$0.04)
Q2 2025	Aug 7, 2025	-$0.42	-$0.37	+10.85%(+$0.05)

ZLAB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.93

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ZLABZai Lab Limited American Depositary Shares	C	C	B	5.8x	5.1%	60.5%	—	$23.19
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Zai Lab Limited American Depositary Shares

Zai Lab is a biopharmaceutical company developing proprietary therapeutics in oncology, autoimmune disease, and infectious disease. The company's clinical pipeline is focused on targeted antibody-drug conjugates, including programs for solid tumors, small cell lung cancer, and neuroendocrine cancers. Key candidates include ZL-1218, ZL-1310, ZL-6301, and ZL-6201, addressing multiple tumor types with novel mechanisms of action.

ZLAB Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.56

Revenue estimate$108.82M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ZLAB Insider Transactions

SellAug 19, 2026
CHEN YAJING
Chief Financial Officer
Shares: 260Value: $7,020
SellAug 12, 2026
LIS WILLIAM DAVID
Director
Shares: 8,506Value: $212,650
SellAug 11, 2026
CHEN YAJING
Chief Financial Officer
Shares: 619Value: $15,475

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals
NEOGNeogen CorpIn Vitro Diagnostics
BEAMBeam Therapeutics Inc. Common StockBiological Products
NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$12.31

High$24.76